Caffeine Consumption Appears to Reduce the Risk of Death in CKD Patients

Results showed that 1283 patients died over a median follow-up of 60 months
Results showed that 1283 patients died over a median follow-up of 60 months

A significant inverse relationship between caffeine consumption and mortality among patients with chronic kidney disease (CKD) was identified in an observational study published in the journal Nephrology Dialysis Transplantation.

Using data from the National Health and Nutrition Examination Survey (1999-2010), researchers evaluated caffeine consumption among 4863 non-institutionalized adults with CKD to determine the association between caffeine intake and mortality in these patients. Patients were grouped based on daily caffeine consumption (Quartile 1 [Q1]: <28.2mg/day; Q2: 28.2–103.0mg/day, Q3: 103.01–213.5mg/day; and Q4: >213.5mg/day); the primary outcome was time to death, while secondary outcomes included time to cardiovascular mortality or cancer mortality (through December 31, 2011).

Related Articles

Results showed that 1283 patients died over a median follow-up of 60 months. Compared with patients who consumed less caffeine (Q1), those who consumed higher levels had nearly a 25% reduction in all-cause mortality (Q2: adjusted hazard ratio [HR] 0.74, 95% CI 0.60–0.91; Q3: HR 0.74, 95% CI 0.62–0.89; Q4: HR 0.78, 95% CI 0.62–0.98; P=.02 for trend across quartiles). Moreover, no significant interaction was noted between caffeine intake and CKD stage or urinary albumin:creatinine ratio with regard to all-cause mortality.

“The reduction in mortality was present even after considering other important factors such as age, gender, race, smoking, other diseases, and diet, “ said Miguel Bigotte Vieira, one of the study's lead authors. “These results suggest that advising patients with kidney disease to drink more caffeine may reduce their mortality. This would represent a simple, clinically beneficial, and inexpensive option, though this benefit should ideally be confirmed in a randomized clinical trial."

For more information visit academic.oup.com.